Source: International Congress 2016 – Cystic fibrosis: various aspects



Rating:

Share or cite this content

Citations should be made in the following way:
Ayesha Aziz (Great Yarmouth, United Kingdom), Ayesha Aziz, Julia Borowicz-Klementowicz, Helen Barker, Christopher Johnson, Nadia Shafi, Charles Haworth, Andres Floto, Uta Hill. Ivacaftor-as effective in clinical practice?. Eur Respir J 2016; 48: Suppl. 60, 1257

Member's Comments

No comment yet.

Related content which might interest you: Implementation of non-medical prescribing within the clinical cystic fibrosis setting Source: International Congress 2014 – Physiotherapy and physical activity in respiratory conditions Year: 2014 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Pulmonary function tests in clinical practice Source: Annual Congress 2013 –PG17 Diagnostic tests for paediatric pulmonologists Year: 2013 The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Modelling and simulation of experimental designs to find the best design of randomized clinical trials in a rare disease: Cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Ability of lung clearance index to track changes in a routine clinical CF setting Source: International Congress 2015 – Paediatric respiratory physiology Year: 2015 The impact of personalised therapies on respiratory medicine Source: Eur Respir Rev 2013; 22: 72-74 Year: 2013 Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions Source: ERJ Open Res, 7 (1) 00448-2020; 10.1183/23120541.00448-2020 Year: 2021 Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018 Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Interpreting lung function in clinical practice Source: Annual Congress 2006 - PG5 - Respiratory physiology: interpreting lung function in health and disease Year: 2006 Effect of different physiotherapy devices on ventilation distribution in adults with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Diagnostic efficiency of sweat conductivity testing in cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence? Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013